Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2019-04-02
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib
that can be given to patients with low or intermediate-1 risk MDS. The safety of this drug
will also be studied, and whether it can help to control the disease.